Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Elranatamab |
Trade Name | |
Synonyms | PF-06863135|PF06863135|PF 06863135 |
Drug Descriptions |
Elranatamab (PF-06863135) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). |
DrugClasses | CD3 Antibody 76 TNFRSF17 Antibody 14 |
CAS Registry Number | NA |
NCIT ID | C146860 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carfilzomib + Elranatamab | Carfilzomib Elranatamab | 0 | 1 |
Daratumumab + Elranatamab | Daratumumab Elranatamab | 0 | 1 |
Daratumumab + Elranatamab + Lenalidomide | Daratumumab Elranatamab Lenalidomide | 0 | 1 |
Elranatamab | Elranatamab | 0 | 6 |
Elranatamab + Nirogacestat | Elranatamab Nirogacestat | 0 | 1 |